Orientation / AKT pathway PI3K / mTOR in the development of prostate cancer and progression

Jun 10, 2016 | | Say something

Orientation / AKT pathway PI3K / mTOR in the development of prostate cancer and progression ;

Some inhibitors of PI3K, Akt and mTOR have been tested as a cancer therapeutic agents alone or in combination with standard therapies and showed sensitizing effects radio-, chemo- and hormone therapy. Credit: Dr. Claudio Festuccia

Targeting PI3K / Akt / mTOR pathway in prostate Road development and progression of cancer: Insight therapy by Dr. Claudio Festuccia (University of L ‘ Aquila, Italy) and published in Drug clinical cancer , volume 3, number 1 – analyzes the experimental and clinical data on the pharmacological inhibition of pathways / Akt mTOR.

These pathways play a key role in the modulation of cell proliferation, tumor growth and survival through phosphorylation of downstream different molecules. tumor growth and progression prostate is negatively regulated by the phosphatase and tensin homologue (PTEN) it is genetically and / or functionally silenced in this neoplasia. The aim of the presentation was to analyze the synthesis and functional characterization of the various inhibitor compounds phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) and Akt activity mTOR, and the feasibility of these inhibitors that work alone or in combination with standard therapies in castration resistant to aggressive prostate cancer (CRPC), a disease that stage of the high percentage of patients with bone metastases is characterized.

Related Post:   The choice of dying at home does not hasten the death of terminally ill cancer patients

Conventional treatment for this stage of the disease requires, in effect, a multidisciplinary approach (medical therapy, surgery and radiation), but is mainly palliative. frequently observed drug resistance. Activation of PI3K / Akt / mTOR pathways plays a significant role in therapy. Blocking this pathway may be necessary to increase standard therapies.

“Several preclinical data support the rationale for advancing the use of pharmacological inhibitors of PI3K / Akt / mTOR in clinical trials in CRPC as performed for various other solid tumors,” said Dr. Festuccia.

This article was originally published on medicalxpress, Read the original article

You may also like:

Posted in: Cancer

Leave a Reply

Your email address will not be published. Required fields are marked *

==[Click 2x to Close X]==
Most Popular Today!